Comparison of reversal and adverse effects of sugammadex and combination of - anticholinergic-anticholinesterase agents in pediatric patients

Journal of Research in Medical Sciences

Volumn 19, Issue 8, 2014, Pages 762-768

  Özgün, Çiğdem ^a   Çakan, Türkay ^a   Baltacı, Bülent ^a   Başar, Hülya ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Atropine; Gamma cyclodextrins; Neostigmine; Neuromuscular nondepolarizing agents

Indexed keywords

ATROPINE; CYCLODEXTRIN; FENTANYL; NEOSTIGMINE; ROCURONIUM; SUGAMMADEX;

ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MONITORING; CHILD; CONSCIOUSNESS LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; EXTUBATION; FEMALE; GENERAL ANESTHESIA; HEAD CIRCUMFERENCE; HEART RATE VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE RELAXATION; MUSCLE SPASM; MUSCLE STRENGTH; NAUSEA; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; OXYGEN DESATURATION; OXYGEN SATURATION; PERIPHERAL NERVE STIMULATOR; RANDOMIZED CONTROLLED TRIAL; SKIN TEMPERATURE; VOMITING;

EID: 84911460523     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Shorten GD. Postoperative residual curarisation: Incidence, aetiology and associated morbidity. Anaesth Intensive Care 1993;21:782-9.
2. Fisher DM. Clinical pharmacology of neuromuscular blocking agents. Am J Health Syst Pharm 1999;56:S4-9.
3. FDA Anesthetic and Life Support Advisory Committee Meeting. Sugammadex Sodium Injection (NDA 22-225) March 11 2008. Briefing Document (Background Package) Organon USA, A part of Schering –Plough Corporation “http://www.fda.gov/ohrms/ dockets/ac/08/brifing/2008-4346b1-02-organon.pdf.
4. Fernández Meré LA, Alvarez-Blanco M. Sugammadex, a novel drug for neuromuscular blockade reversal. Rev Esp Anestesiol Reanim 2010;57:95-102.
5. Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth 2009;103:115-29.
6. Yang LP, Keam SJ. Sugammadex: A review of its use in anaesthetic practice. Drugs 2009;69:919-42.
7. Adam JM, Bennett DJ, Bom A. Clark JK, Feilden H, Hutchinson EJ, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: Synthesis and structure-activity relationships. J Med Chem 2002;45: 1806-16.
8. Hogg RM, Mirakhur RK. Sugammadex. A selective relaxant binding agent for reversal of neuromuscular block. Expert Rev Neurother 2009;9:599-608.
9. Cameron KS, Clark JK, Cooper A, Fielding L, Palin R, Rutherford SJ, et al. Modified gamma-cyclodextrins and their rocuronium complexes. Org Lett 2002;4:3403-6.
10. Pedersen T, Viby-Mogensen J, Ringsted C. Anaesthetic practice and postoperative pulmonary complications. Acta Anaesthesiol Scand 1992;36:812-8.
11. Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997;41:1095-103.
12. Caldwell JE. The continuing search for a succinylcholine replacement. Anesthesiology 2004;100:763-4.
13. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: A randomized comparison with neostigmine. Anesthesiology 2008; 109:816-24.
14. Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gómez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: A multicenter, randomized, controlled trial. Anesth Analg 2010;110:64-73.
15. Plaud B, Meretoja O, Hofmockel R, Raft J, Stoddart PA, van Kuijk JH, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009;110:284-94.
16. Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth 2008;100:622-30.
17. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: A dose-finding and safety study. Anesthesiology 2006;104:667-74.
18. Woo T, Kim KS, Shim YH, Kim MK, Yoon SM, Lim YJ, et al. Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients. Korean J Anesthesiol 2013;65:501-7.
19. Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: Results of a randomised, controlled trial. Eur J Anaesthesiol 2010;27:874-81.
20. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: A comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 2007;104:569-74.
21. Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev 2009:CD007362.
22. Ledowski T, Hillyard S, O’Dea B, Archer R, Vilas-Boas F, Kyle B. Introduction of sugammadex as standard reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcome. Indian J Anaesth 2013;57:46-51.